MTOR and pneumonitis: Although numerous PI3K/AKT/mTOR pathway inhibitors have been extensively studied, their potential adverse effects, such as severe hepatotoxicity and pneumonitis, have largely restricted the clinical application of these inhibitors (Zhang et al., 2019).